Repurposing FDA-Approved Drugs to Modulate DNA Repair in CRISPR

Study Background and Research Question

DNA double-strand breaks (DSBs) are a central event in genome editing, cancer therapy, and disease modeling. While DSBs occur spontaneously from endogenous processes or can be induced by agents such as ionizing radiation, the CRISPR-Cas9 system enables precise, targeted DSBs at defined genomic loci. Cellular repair of these breaks is dominated by non-homologous end joining (NHEJ) and microhomology-mediated end joining (MMEJ), both of which can introduce indels and larger genomic rearrangements. Homology-directed repair (HDR), in contrast, provides a template-driven path for precise genome modifications but is generally less efficient. Thus, the ability to pharmacologically steer DNA repair pathway choice is highly relevant for improving the precision and safety of genome editing, as well as for leveraging synthetic lethality in cancer treatment. The reference study addresses whether clinically approved drugs can be repurposed to modulate these repair outcomes, enhancing both research and therapeutic applications.

Key Innovation from the Reference Study

The core innovation lies in the systematic screening of over 7,000 FDA-approved drugs to identify modulators of DSB repair pathway choice in human induced pluripotent stem cells (iPSCs) undergoing CRISPR editing. Unlike prior research that focused on single classes of DNA repair inhibitors, this study offers a comprehensive resource linking drug action to shifts in NHEJ, MMEJ, and HDR outcomes. Furthermore, the study uncovers novel regulatory roles for proteins such as estrogen receptor 2 (ESR2) and aldehyde oxidase 1 (AOX1) in DNA repair, and demonstrates how silencing ESR2 can synergize with NHEJ inhibition to substantially increase HDR rates. These findings open new avenues for both genome editing and synthetic lethality-based cancer therapies.

Methods and Experimental Design Insights

The authors utilized a high-content screening approach in 409B2 human iPSCs engineered to express a doxycycline-inducible Cas9 (iCRISPR). During drug treatment, cells were targeted at the FRMD7 genomic locus. After editing, cell survival was measured via a resazurin fluorescence assay, and DNA was extracted for high-throughput Illumina sequencing. Editing outcomes were computationally assigned to NHEJ (indels with <2 bp microhomology), MMEJ (deletions with ≥2 bp microhomology), or HDR (precise edits using exogenous donor templates). Each drug condition was run in a single replicate, covering a total of 7,240 conditions. This design enabled the quantification of how each drug shifted the frequency and character of DNA repair outcomes relative to DMSO controls.

Core Findings and Why They Matter

Screening revealed that numerous FDA-approved drugs can act as either inhibitors or enhancers of specific DSB repair outcomes. For instance, some compounds increased the frequency of HDR, thereby improving the precision of genome editing, while others promoted NHEJ or MMEJ, which may be valuable for gene knockout strategies. Notably, the study identified that inhibition of NHEJ with established inhibitors (e.g., DNA-PKcs inhibitors) in combination with ESR2 silencing produced a mean 4.6-fold increase in HDR rates. Additionally, certain drugs induced synthetic lethality when NHEJ or HDR was blocked, pointing to precision medicine strategies for targeting cancer cells with specific repair defects. The ability to pharmacologically control repair outcomes is thus relevant not only for gene therapy and disease modeling but also for advancing immuno-oncology (e.g., CAR-T cell engineering) and the development of targeted cancer treatments.

Comparison with Existing Internal Articles

Internal resources such as Repurposing Clinically Safe Drugs to Guide DNA Repair in CRISPR and Repurposing Approved Drugs to Modulate DNA Repair in CRISPR Editing provide further context and practical details for implementing drug-based modulation of DNA repair. These articles elaborate on actionable strategies for steering genome editing outcomes and troubleshooting issues such as cell viability and assay reproducibility. For researchers focused on calcium signaling modulation or disease modeling, articles like Dantrolene Sodium Salt: Precision Ryanodine Receptor Antagonist Use discuss the role of ryanodine receptor antagonists in dissecting intracellular calcium dynamics, which is relevant in the context of CRISPR, neurodegenerative disease, and ischemia research. Collectively, these resources underscore the growing toolkit for pharmacological modulation in advanced cellular models.

Limitations and Transferability

While the breadth of the drug screen is a major strength, several limitations are worth noting. First, the study utilized a single iPSC line and a single genomic target, which may not fully capture cell type- or locus-specific repair dynamics. Drug effects were only assessed in a single replicate per condition, limiting statistical power for rare outcomes. Importantly, the pharmacological conditions optimized in iPSCs may not directly translate to primary cells, in vivo models, or clinical contexts without further validation. Furthermore, while the screen identified candidates that modulate repair, mechanistic dissection for most hits remains incomplete. Transferability to other systems—such as neurodegenerative disease models or ischemia and hypoxia research—requires careful titration and mechanistic follow-up, especially where DSBs and calcium signaling intersect.

Protocol Parameters

• Cell line selection: Human iPSCs (e.g., 409B2) expressing inducible Cas9 for genome editing studies.
• Drug treatment timing: Apply candidate compounds during the window of CRISPR-induced DSB formation and repair (e.g., 1–24 hours post-nuclease induction).
• Editing locus: Target loci (e.g., FRMD7) with established gRNAs; consider locus-specific repair variability.
• Cell survival assay: Use resazurin fluorescence for high-throughput viability screening post-editing.
• Outcome quantification: Assign sequencing reads to NHEJ, MMEJ, or HDR by indel pattern and microhomology analysis; validate with orthogonal methods if feasible.
• Follow-up validation: Re-test promising drug hits in multiple cell types and loci, and consider dose-response relationships.

Why this cross-domain matters, maturity, and limitations

The intersection of DNA repair modulation and advanced disease modeling—such as neurodegenerative disease or ischemia models—relies on the same core principle: precise control of intracellular signaling and repair outcomes. Modulators like ryanodine receptor antagonists, including dantrolene sodium salt, are highlighted for their role in calcium signaling, which can influence DSB repair pathway choice and cell fate. However, direct transfer of DNA repair modulators from genome editing workflows to complex disease models requires validation, as cellular context and repair machinery can differ substantially. The maturity of these approaches is highest in engineered cell lines and preclinical models, with translational potential for therapeutic genome editing and synthetic lethality in oncology.

Outlook

This large-scale pharmacological screen provides a valuable catalog for researchers seeking to enhance precision in genome editing and to explore synthetic lethality in cancer models. As highlighted in both the reference study and internal reviews, the ability to direct DNA repair outcomes with clinically safe compounds advances disease modeling, gene therapy, and targeted cancer treatment. Further mechanistic studies and validation across diverse cell types and disease contexts will be essential to realize the full translational potential of these findings.

Research Support Resources

To support workflows involving calcium signaling modulation or DSB repair pathway analysis, researchers may consider using Dantrolene, sodium salt (SKU B6329), a potent ryanodine receptor antagonist with nanomolar activity and well-characterized calmodulin-dependent inhibition. According to the product information, it is suitable for studies investigating intracellular calcium dynamics and has been utilized in models of neurodegeneration, ischemia, and pancreatitis. For additional protocol guidance and troubleshooting tips, relevant internal articles further detail how such compounds can be integrated into genome editing and disease modeling assays. APExBIO provides quality control data to ensure experimental reproducibility when selecting this compound for advanced research applications.